drugset / Trial / NCT01916187

Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma

NCT01916187

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the best dose of imetelstat when given alone for patients with neuroblastoma and also when given in combination with 13-cis-retinoic acid.

Timeline

Start
2013-07-30
Primary completion
2013-11-22
Completion
2014-01-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Imetelstat Oligonucleotide (other) 285 mg/m2 Intravenous

Indications